BR112012027520A2 - formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino - Google Patents

formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino

Info

Publication number
BR112012027520A2
BR112012027520A2 BR112012027520A BR112012027520A BR112012027520A2 BR 112012027520 A2 BR112012027520 A2 BR 112012027520A2 BR 112012027520 A BR112012027520 A BR 112012027520A BR 112012027520 A BR112012027520 A BR 112012027520A BR 112012027520 A2 BR112012027520 A2 BR 112012027520A2
Authority
BR
Brazil
Prior art keywords
males
formulations
hydroxy
treatment
acid derivatives
Prior art date
Application number
BR112012027520A
Other languages
English (en)
Portuguese (pt)
Inventor
Enoch Bortey
Lorin Johnson
William Forbes
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44861888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012027520(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Priority to BR122014009845A priority Critical patent/BR122014009845A2/pt
Publication of BR112012027520A2 publication Critical patent/BR112012027520A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012027520A 2010-04-26 2011-04-26 formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino BR112012027520A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122014009845A BR122014009845A2 (pt) 2010-04-26 2011-04-26 usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32815110P 2010-04-26 2010-04-26
PCT/US2011/033905 WO2011137103A1 (en) 2010-04-26 2011-04-26 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Publications (1)

Publication Number Publication Date
BR112012027520A2 true BR112012027520A2 (pt) 2015-09-15

Family

ID=44861888

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012027520A BR112012027520A2 (pt) 2010-04-26 2011-04-26 formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino
BR122014009845A BR122014009845A2 (pt) 2010-04-26 2011-04-26 usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122014009845A BR122014009845A2 (pt) 2010-04-26 2011-04-26 usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa

Country Status (9)

Country Link
US (3) US8497256B2 (enExample)
EP (1) EP2563117B1 (enExample)
JP (1) JP2013525440A (enExample)
AU (1) AU2011245455A1 (enExample)
BR (2) BR112012027520A2 (enExample)
CA (1) CA2797560A1 (enExample)
IL (1) IL222642A0 (enExample)
MX (1) MX358142B (enExample)
WO (1) WO2011137103A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801489A4 (en) 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of autoimmune disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US326364A (en) 1885-09-15 Electric-lamp hanger
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
DE3887353T2 (de) 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US5905073A (en) 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
SE9700934D0 (sv) 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
WO1998043667A1 (en) 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2586427A3 (en) 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate

Also Published As

Publication number Publication date
US20120058184A1 (en) 2012-03-08
WO2011137103A1 (en) 2011-11-03
EP2563117A4 (en) 2013-09-04
IL222642A0 (en) 2012-12-31
CA2797560A1 (en) 2011-11-03
BR122014009845A2 (pt) 2015-12-29
MX358142B (es) 2018-08-06
AU2011245455A1 (en) 2012-11-15
EP2563117A1 (en) 2013-03-06
EP2563117B1 (en) 2018-02-21
US20150132381A1 (en) 2015-05-14
US8497256B2 (en) 2013-07-30
JP2013525440A (ja) 2013-06-20
MX2012012324A (es) 2013-01-29
US20130295178A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
BR112015011830A2 (pt) compostos e seus métodos de utilização
CU20140025A7 (es) Pirimidinas anilladas sustituidas
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
EA201201648A1 (ru) Стимуляторы sgc
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
MX391043B (es) Formulaciones de anticuerpo y metodos.
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112012033755A2 (pt) composições e métodos antissépticos estáveis
CR20140594A (es) Composiciones farmacéuticas y tratamiento de mastitis
BR112014014939A2 (pt) composição de tratamento de sementes
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112014017587A2 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112014009760A8 (pt) análogos de ácido siálico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 33/26

Ipc: A61K 31/655 (2006.01), A61K 9/28 (2006.01), A61K 9

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.